From: Billi Goldberg <bigoldberg@igc.apc.org>
Subject: Index to CATIE #12-23
Note: Copyright 1992, Dan R. Greening. Non-commercial reproduction allowed.
Archive-Number: 5934
Organization: unspecified
Date: Wed, 19 Aug 92 07:36:48 PDT

CATIE issues #12 to 33 are availble from the HIV/AIDS Info
BBS (714) 248-2836 or the Seattle AIDS Info BBS at 206-323-4420.
CATIE's stuff is really great and they provide journal research 
references for their article
************************************************************************

INDEX ISSUES #12-33 OF COMMUNITY AIDS TREATMENT INFORMATION EXCHANGE
(CATIE) FROM TORONTO, ONTARO, CANADA.  SEAN HOSSEIN IS THE EDITOR.

<33>  Treatment Update 33 May 92 
          I. ANTI-HIV AGENTS 
          A. AZT and dementia 
          B. HIV, mycoplasma and dementia 
          C. AZT, ddI and muscle damage 
          II. IMMUNOMODULATORS 
          A. Carnitine for muscle loss? 
          B. CD8+ cells: therapy for KS? 
          III. INFECTION FIGHTERS 
          A. Changing landscape of vaginal yeast infections 
          B. Clinical trial of friendly bacteria in Canada 

<32>  Treatment Update 32, April 92 
          I. ANTI-HIV AGENTS 
          A. AZT, HIV and the intestine 
          B. AZT and interferon 
          C. AZT, ddC, and interferon: NIH studies toxic effects 
          II. IMMUNOMODULATORS 
          A. Thalidomide and ulcers 
          III. INFECTION FIGHTERS 
          A. Digestive Tract problems and some solutions 
          IV. ANTI-CANCER AGENTS 
          A. Hyperthermia for KS - a phase I trial 
          V. TESTING 
          A. Bio-rhythms found to affect interferon therapy 
          B. Measuring triglycerides -- cheaper than interferon? 

<31>  Treatment Update 31, March 92 
          I. ANTI-HIV AGENTS 
          A. Passive immunotherapy for HIV 
          B. Discoverer of HIV studies passive immunotherapy 
          II. IMMUNOMODULATORS 
          A. DHEA for diarrhea? 
          B. Disappearing T-cells 
          C. Autoimmunity: clues for treatment 
          D. Interferon: more than just an antiviral 
          E. Acid-labile interferon 
          F. Interferon as problematic 
          G. Interferon: predicting illness 
          H. Reducing excessive interferon with naltrexone 
          I. Reducing excessive interferon with AZT 
          III. INFECTION FIGHTERS 
          A. Clarithromycin - interactions with food 
          IV. TESTING 
          A. Looking for MAC 
          B. DHEA: predicting AIDS 

<30>  Treatment Update 30, Feb. 1992 
          I. ANTI-HIV AGENTS 
          A. AZT: 2-year study on early versus later use 
          B. AZT failure: resistance theory questioned 
          II. IMMUNOMODULATORS 
          A. Autoimmunity and HIV 
          B. Danazol for platelets 
          C. Danazol and CD4/CD8 ratios 
          III. INFECTION FIGHTERS 
          A. Foscarnet versus ganciclovir for CMV 
          B. Reducing resistance to ganciclovir 
          C. Women: Pelvic inflammatory Disease (PID) 
          D. PID: diagnostic problems 
          E. Treatments for PID 
          F. MAC: Rifabutin and liver enzymes, helping to predict 
             survival 

<29>  Treatment Update 29, December 1991 
          ANTI-HIV AGENTS;  AZT and ddC; AZT and Nutritional 
Complications 
          Immunomodulators: Imreg-1  Improvements in Quality of Life 
          Immunomodulators: Specific Nutrients and HIV/AIDS 
          Immunomodulators: Changes in Zinc and Copper 
          Immunomodulators: Vitamin B6 and Immune Function 
          Immunomodulators: Vitamin B12 and Quality of Life 
          Immunomodulators: Folic Acid and Cervical Cancer 
          Immunomodulators: Helpful Sugar from Yeast 
          Immunomodulators: "Friendly" Yeast for Diarrhea? 
          INFECTION FIGHTERS  Sparfloxacin for TB and MAC 
          TEST  Colposcopy Study Raises Questions About Pap Smears 

<28>    Treatment Update 28, November 1991 
         I.  ANTI-HIV AGENTS 
         A.  Dextran sulphate 
         B.  ddI: Preventing Peripheral Neuropathy 
         C.  Biotin for Peripheral Neuropathy? 
         D.  ddI: Avoiding Pancreatitis 
         II.  INFECTION FIGHTERS 
         A.  Azithromycin for MAC 
         III.  ANTI-CANCER 
         A.  Boosting the Immune System Against Cancer 
         B.  Interleukin-2 for Lymphoma 
         C.  GM-CSF May Improve Quality of Life 
         IV.  TESTING 
         A.  Predicting Cancer with CD19+? 
         B.  DHEA and Immune Deficiency 
          
<27>    Treatment Update, Oct. 1991 
         I. ANTI-HIV AGENTS 
         A. Ozone 
         B. A Clinical Trial of Ozone in Canada 
         II. IMMUNE BOOSTERS 
         A. Skin Infections and HIV 
         B. DNCB--Uses and Risk/Benefits 
         C. DNCB as Therapy for HIV 
         D. DNCB--No Patient So No Financial Incentive for Trials 
         E. Hemophilia: Clotting Concentrates and Autoimmunity 
         F. Hemophilia--A Clinical Trial of Concentrates 
         G. Boosting the Immune System Against TB/MAC 
         H. Carnitine for TB--A Randomized Trial 
         III. INFECTION FIGHTERS 
         A. Tuberculosis 
         B. Combination Therapy for MAC 
         C. Toxo: Clarithromycin and Pyrimethamine 
         IV. TESTING 
         A. EPO, HIV and Anemia 
          
<26>    Treatment Update 26 - September 1991 
         I.  ANTI-HIV AGENTS 
         A.  AZT: Danish Study Suggests Supplementary Antibodies 
         B.  AZT and Antibodies--A Randomized Trial 
         C.  AZT: Second Study Confirms "Cellular Resistance" 
         D.  AZT and Suppression of Interferon-alpha: A Shifting 
             Risk/Benefit Ratio? 
         E.  AZT: Mutations Prevented with Interferon-beta 
         F.  AZT and food 
         G.  AZT: Bacterial Resistance in Patients 
         II.  INFECTION FIGHTERS 
         A.  Drugs for Diarrhea 
         B.  Immune Booster with Erythromycin for Crypto 
         C.  Humatin (Paromomycin) for Crypto 
         D.  Sandostatin/Octreotide for Diarrhea 
          
<25>    Treatment Update 25 - August 1991 
         I.  Anti-HIV AGENTS 
         A.  How and why ddI gets approved. 
         B.  Friendly bacteria may fight virus, especially in women. 
         C.  AZT - a new benefit? 
         D.  TIBO: promising human studies 
         II.  IMMUNE BOOSTERS 
         A.  Autoimmunity, platelets, and HIV. 
         B.  Dapsone for platelets. 
         III.  ANTI-CANCER 
         A.  Lymphoma - trends in incidence, age, race and sex. 
         B.  Non-Hodgkin's lymphoma in users of AZT. 
         C.  Treatments for lymphoma. 
         D.  Low-dose chemo for lymphoma. 
          
<24>    Treatment Update 24, June 1991 (ISSN 11817186) 
         I ANTI-HIV AGENTS 
         A. AZT and ddI 
         B. AZT: 400 mg/day just as good as 1200 mg/day? 
         C. AZT resistance: impliP2Cons for length of therapy 
         D. Intermittent versus continuous AZT 
         E. Alternating AZT, acyclovir, ddI, and ddC 
         F. Low-dose oral alpha interferon 
         II IMMUNE BOOSTERS. 
         A. Chemical messages from the brain 
         B. Imreg 1 in ARC 
         C. MEK for ARC 
         D. Vitamin A, the immune system, and retroviruses 
         E. Beta carotene and the immune system 
         F. High-dose Beta carotene helps CD4+ cells 
         G. EPO as immune booster 
         III INFECTION FIGHTERS 
         A. CMV 
         B. Intermittent DHPG for CMV 
         C. Overcoming CMV resistance: dual therapy with foscarnet and 
            DHPG 
         E. Green algae extract for CMV? 
          
<23>    Treatment Update #23, May 1991 (ISSN 11817186) 
         I. ANTI HIV-AGENTS 
         A. Harvard team finds antivirals immunosuppressive 
         II IMMUNE BOOSTERS 
         A. Antioxidants, HIV, and AIDS 
          
         B. Co-enzyme Q10 for treatment of ARC 
         C. Co-enzyme Q10 : absorption, dose, and side effects 
         III. INFECTION FIGHTERS 
         A. PCP prophylaxis 
         B. Low dose Bactrim/Septra for PCP prevention 
         C. 566C80-a parasite killer 
         D. AIDS, allergies, and sulpha drugs 
         E. Desensitization to Sulphadiazine 
         F. Bactrim/Septra desensitization 
         IV. TESTING 
         A. At risk for PCP 
         B. Lab markers predict PCP 
         C. Screening for Toxo 
          
<22>    Treatment Update #22, April 1991 (ISSN 11817186) 
         I. ANTI-HIV AGENTS 
         A. Compound Q/GLQ 223 
         B. Clinical trials of compound Q/GLQ 223 
         C. Compound Q: data analysis raises questions 
         D. Syphilis drug for HIV? 
         II. IMMUNE BOOSTERS 
         A. Tuftsin and the immune system 
         B. Tuftsin and the spleen 
         C. Deficiency of tuftsin in AIDS 
         D. Tuftsin used in Israel 
         III. INFECTION FIGHTERS 
         A. Sparfloxacin, Cipro, and French abortion drug for MAC 
         B. Combinations for MAC 
         C. Clarithromycin combinations and MAC 
         D. Clarithromycin available in Canada 
          
<21>    Treatment Update #21, February 1991 (ISSN 11817186) 
         I. ANTI-HIV AGENTS 
         A. Mycoplasma and HIV -- new research strengthens link 
         B. Japanese antibiotic for HIV 
         C. AZT as antibiotic 
         D. Hyssop -- a new herb against HIV 
         II. IMMUNE BOOSTERS 
         A. Cimetidine -- an overview 
         B. Cimetidine for herpes 
         III. INFECTION FIGHTERS 
         A. Drugs for toxo 
         B. Dapsone for toxo 
         C. Doxycycline for toxo? 
         E. Cimetidine for dapsone toxicity 
         IV. ANTI-CANCER AGENTS 
         A. Cimetidine -- a pilot study 
         B. Antibiotics for KS? 
          
<20>    Treatment Update #20, January 1991 (ISSN 11817186) 
         I. ANTI-HIV AGENTS 
         A. Understanding AZT failure and moving beyond mono-therapy 
         II. IMMUNE BOOSTERS 
         A. Discoverer of HIV studies Chinese herbs 
         B. Imuthiol and AIDS/ARC 
         C. Imuthiol -- a pilot study 
         D. Intravenous Imuthiol -- which dose is best? 
         E. Oral Imuthiol and AZT in AIDS/ARC 
         III. INFECTION FIGHTERS 
         A. High-dose gamma globulin for AIDS/ARC 
         B. Long-term use of gamma globulin for AIDS/ARC 
         C. Gamma globulin for ARC 
         D. Gamma globulin for anaemia caused by parvovirus infection 
         IV. ANTI-CANCER AGENTS 
         A. Kaposi's sarcoma -- a shift in perspective 
         B. Cancer therapy -- a glimpse of the future 
         C. Pentosan polysulphate enters clinical trials 
         V. TESTING 
         A. AZT, activated T-cells, and disease progression. 
         B. Activated T-cells, Beta2-microglobulin, and disease 
            progression. 
          
<19>    Treatment Update #19, December 1990 
         I. ANTI-HIV AGENTS 
         A. AZT: 3,000 mg/day 
         B. AZT: 600 mg/day for AIDS 
         C. AZT: 300 mg/day in ARC 
         II. INFECTION FIGHTERS 
         A. Steroids and PCP 
         B. Consensus on Steroids for PCP 
         C. Fluconazole and fungal infections 
         D. Fluconazole vs Amphotericin B for cryptococcal meningitis 
         E. Fungal infections, HIV and women 
         F. Fluconazole vs. clotrimazole for oral fungal infections 
         G. Fluconazole: maintenance therapy for oral candida 
         H. Fluconazole: once per week as prophylaxis against candida 
          
<18>    Treatment Update # 18, November 1990 
         I. ANTI-HIV AGENTS 
         A. Vitamin C found to inhibit HIV repliP2Con 
         B. ddI: long-term use and toxicity 
         C. ddI and very ill patients 
         II. IMMUNE BOOSTERS 
         A. Broncho-Vaxom may help immunity 
         B. Levamisole and HIV 
         III. INFECTION FIGHTERS 
         A. Dapsone-TMP for PCP 
         IV. ANTI-CANCER AGENTS 
         A. Interferon-alpha with AZT for KS 
          
<17>    Treatment Update # 17, October 1990 
         I. ANTI-HIV AGENTS 
         A. AZT: Treatment or prophylaxis? 
         B. AZT versus THA: results from France look promising for THA 
         C. AZT: Cancer Risk? 
         D. AZT: Viral resistance has serious impliP2Cons for early 
            intervention 
         E. AZT: Early intervention in Canada and the USA results in no 
            difference in disease progression 
         F. AZT: Early intervention is problematic 
         G. AZT: Ethical problems for ddI/AZT trials 
         II. IMMUNE BOOSTERS 
         A. The thymus gland and HIV 
         B. Thymopentin may delay progression to AIDS 
         C. Increasing thymic hormone release with amino acids 
         III. VACCINES 
         A. HGP-30: Vaccines as therapy 
          
<16>    Treatment Update # 16, September 1990 (ISSN 1181-7186) 
         I. ANTI-HIV AGENTS 
         A. FDA approves a large clinical trial of extracorporeal 
            photopheresis 
         B. Interferon-alpha in early HIV disease 
         C. Clinical trial of oral Interferon-alpha in Toronto 
         II. IMMUNE BOOSTERS 
         A. Polio vaccine may delay HIV disease progression 
         B. NAC enters clinical trials 
         III. ANTI-CANCER AGENTS 
         A. Clinical trial of Salk polio vaccine therapy for Kaposi's 
            sarcoma 
         IV. CO-FACTORS 
         A. Clinical trial of antibiotics against mycoplasma 
          
<15>    Treatment Update # 15, August 1990 
         I. ANTI-HIV AGENTS 
         A. Low-dose AZT 
         B. AZT and Hypericin 
         C. Side Effects of ddI 
         D. ddI - once per day the better way? 
         E. ddI as Antibiotic 
         F. Long-term use of ddI 
         II. IMMUNE BOOSTERS 
         A. Isoprinosine for asymptomatics? 
         B. Isoprinosine and the FDA 
         III. INFECTION FIGHTERS 
         A. Oral Ganciclovir for CMV retinitis 
          
<14>    Treatment Update # 14, May 1990 
         I. ANTI-HIV DRUGS 
         A. Tetracycline, HIV, and Mycoplasma 
         B. AZT: the effective dose gets lower and lower 
         II. IMMUNE BOOSTERS 
         A. Imuthiol, Antabuse, and AIDS/ARC 
         III INFECTION FIGHTERS 
         A. Multiple drug therapy for MAC 
         IV. CO-FACTORS 
         A. From VLIA to Tetracycline and Mycoplasma 
          
<13>    Treatment Update # 13, April 1990 
         I. ANTI-HIV DRUGS 
         A. TIBO--new, low toxic anti-HIV drugs 
         B. Drugs for HIV-protease 
         C. AL-721 
         D. Vitamin C, anti-oxidants and AIDS 
         E. French research on CD16 leads to a pilot study 
         II. Immune Boosters 
         A. French researchers study zinc for ARC 
         III. infection fighters 
         A. MAC--drug available in Yugoslavia 
         IV. vaccines 
         A. Pneumonia vaccine 
         V. Testing 
         A. Elispot, a new test? 
         B. Monitoring AZT and chemotherapy toxicity 
          
<12>    Treatment Update # 12, March 1990 
         I. ANTI-HIV DRUGS 
         A. Tamoxifen: keeping HIV latent 1 
         B. Clinical Trials of Soluble CD4 
         C. PMEA 2 
         II. IMMUNE BOOSTERS 
         A. German Trial of Cimetidine for ARC 
         B. ACTH and Isoprinosine for AIDS 
         III. ANTI-CANCER AGENTS 
         A. Kaposi's sarcoma -- a big puzzle 
         IV. Testing 
         A. Beta2-microglobulin and disease progression 
          
Subscription Info.

Community AIDS Treatment Information Exchange (CATIE)
Suite 324 - 517 College Street
Toronto, Ontario M6G 4A2
(416) 944-1916

Back issues are $1.50 each.  Year's subscription is $15.00.

For those who cannot afford to pay anything, the fee is waived.